Clinical retrospective study of infections by DHA-1 plasmid-mediated AmpC β-lactamase

LI Qing,JIANG Yanqun,LI Yi,TANG Jin,WANG Jianqiang,ZHUANG Yihui
DOI: https://doi.org/10.3969/j.issn.1673-8640.2008.03.002
IF: 1.865
2008-01-01
Laboratory Medicine
Abstract:Objective To investigate the clinical features of DHA-1 plasmid-mediated AmpC β-lactamase isolates in our hospital,and analyze the drug susceptibility and the molecular epidemiology.Methods The clinical data of 34 patients infected by Escherichia coli and Klebsiella pneumoniae producing DHA-1 plasmid-mediated AmpC β-lactamase was collected from 2003 to 2005,polymerase chain reaction(PCR) was used to detect DHA-1 structure gene.Random amplified polymorphic DNA(RAPD)was performed to investigate the patterns of 34 isolates,and minimal inhibitory concentration(MIC) was used to determine the drug susceptibility.Results The risk factors included the age,immunosuppressive agent therapy,history of wound or operation and so on.The failure rate of treatment with three generations of cephalosporins was 86.9%(ceftazidime 88.9%,cefotaxime 60% and cefoperazone100%),β-lactam-β-lactamase inhibitor combinations 71.4%,carbapenems 10%,fluoroquinolones 70%.DHA-like was DHA-1 by means of sequencing and blasting.RAPD patterns indicated the prevalence of DHA-1 producing isolates among departments.Conclusions The failure rate of treatment with antibiotics is relatively high.Isolates from different departments or from the same department show certain homology.
What problem does this paper attempt to address?